Research into central nervous system (CNS) disorders is currently a priority for the pharmaceutical research and development industry and one of Kendle’s key strengths. We are world leaders in designing and conducting critical abuse liability studies and in evaluating the neurocognitive and behavioral effects of CNS drugs. Our scientific team includes internationally recognized opinion leaders with a diverse base of preclinical and clinical knowledge.
We have developed a variety of specialty population patient databases, including those with dementia and drug use disorders, helping to ensure your study reaches its enrollment targets In addition, we have developed our own proprietary software system that has been specifically designed to measure numerous parameters, such as reaction times, memory, attention, etc.